Actively Recruiting
Worldwide COVID-19 in Children and Adult Patients With Primary ImmunoDeficiencies (PID) Survey
Led by Imagine Institute · Updated on 2025-03-05
200
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the impact of COVID-19 infection on individuals with primary immunodeficiencies (PID), a group for which little information currently exists. The study builds on an earlier survey phase and aims to gather detailed data on how COVID-19 affects survival, hospitalizations, and oxygen therapy needs among PID patients. This observational survey is conducted through a secure online platform and involves global participation by healthcare professionals. The study collects retrospective data from health care providers who enter patient information on a GDPR-compliant system. It focuses on patients of all ages diagnosed with PID and affected by COVID-19. The survey gathers extensive clinical details to better understand outcomes such as ICU admissions and post-infection sequelae. Participants are represented by their healthcare providers who document various outcomes including survival, ICU admission rates, and oxygen therapy use at baseline, as well as longer-term effects. The study began in March 2020 and will continue through February 2027. The data collection is designed to adapt as new knowledge of the pandemic emerges, enhancing understanding of COVID-19's effects on this vulnerable population.
CONDITIONS
Brief Title
COVID-19 in PID Survey
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with a Primary Immune Deficiency
- Proven or probable COVID-19 infection
You will not qualify if you...
- Secondary Immune Deficiency
- Other Coronavirus infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 5 years
Participants who have Primary Immune Deficiency and COVID-19 infection are observed to collect data on their health outcomes.
Trial Site Locations
Total: 1 location
1
Imagine Institute
Paris, France, 75015
Actively Recruiting
Research Team
N
Nizar MAHLAOUI, MD, MPH, PhD
H
Hassan FAOUR, BS
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here